These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 15332287

  • 21. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
    Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.
    J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
    [Abstract] [Full Text] [Related]

  • 22. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation.
    Chan HL, Chui AK, Lau WY, Chan FK, Wong ML, Tse CH, Rao AR, Wong J, Sung JJ.
    J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406
    [Abstract] [Full Text] [Related]

  • 23. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains.
    Hosseini SY, Sabahi F, Amini-Bavil-Olyaee S, Alavian SM, Merat S.
    J Virol Methods; 2006 Nov; 137(2):298-303. PubMed ID: 16962669
    [Abstract] [Full Text] [Related]

  • 24. Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy.
    Ding C, Wong VW, Chow KC, Chan HY, Hui AY, Wong GL, Lo YM, Sung JJ, Chan HL.
    Antivir Ther; 2006 Nov; 11(8):1041-9. PubMed ID: 17302374
    [Abstract] [Full Text] [Related]

  • 25. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B.
    Feng B, Wei L, Chen M, Wang L.
    Microbiol Res; 2008 Nov; 163(4):487-92. PubMed ID: 17317127
    [Abstract] [Full Text] [Related]

  • 26. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
    Shin JW, Chung YH, Choi MH, Kim JA, Ryu SH, Jang MK, Kim IS, Park NH, Lee HC, Lee YS, Suh DJ.
    J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
    [Abstract] [Full Text] [Related]

  • 27. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
    Yeh CT, Chien RN, Chu CM, Liaw YF.
    Hepatology; 2000 Jun; 31(6):1318-26. PubMed ID: 10827158
    [Abstract] [Full Text] [Related]

  • 28. Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection.
    Ramezani A, Velayati AA, Roshan MR, Gachkar L, Banifazl M, Keyvani H, Aghakhani A.
    Int J Infect Dis; 2008 May; 12(3):252-5. PubMed ID: 17954033
    [Abstract] [Full Text] [Related]

  • 29. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F, Akuta N, Suzuki Y, Sezaki H, Arase Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Watahiki S, Kumada H.
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [Abstract] [Full Text] [Related]

  • 30. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
    Sun J, Wang Z, Ma S, Zeng G, Zhou Z, Luo K, Hou J.
    J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
    [Abstract] [Full Text] [Related]

  • 31. Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients.
    Woo HY, Park H, Kim BI, Jeon WK, Cho YK, Kim YJ.
    Antivir Ther; 2007 Mar; 12(1):7-13. PubMed ID: 17503742
    [Abstract] [Full Text] [Related]

  • 32. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
    Tsubota A, Arase Y, Suzuki F, Kobayashi M, Matsuda M, Sato J, Suzuki Y, Akuta N, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H.
    J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
    [Abstract] [Full Text] [Related]

  • 33. A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine.
    Ide T, Kumashiro R, Koga Y, Tanaka E, Hino T, Hisamochi A, Murashima S, Ogata K, Tanaka K, Kuwahara R, Sata M.
    Am J Gastroenterol; 2003 Sep; 98(9):2048-51. PubMed ID: 14499786
    [Abstract] [Full Text] [Related]

  • 34. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients.
    Pollicino T, Isgrò G, Di Stefano R, Ferraro D, Maimone S, Brancatelli S, Squadrito G, Di Marco V, Craxì A, Raimondo G.
    Antivir Ther; 2009 Sep; 14(5):649-54. PubMed ID: 19704167
    [Abstract] [Full Text] [Related]

  • 35. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
    Cho SW, Hahm KB, Kim JH.
    Hepatology; 2000 Nov; 32(5):1163-9. PubMed ID: 11050070
    [Abstract] [Full Text] [Related]

  • 36. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH, Lu SN, Chen CH, Wang JH, Wu CM, Hung CH, Tseng PL, Hu TH, Changchien CS, Lee CM.
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [Abstract] [Full Text] [Related]

  • 37. [Determination of the lamivudine-resistant mutants of hepatitis B virus].
    Gervain J, Papp I, Csöndes M, Nemesánszky E, Rácz I, Ribiczey P, Telegdy L, Tornai I, Weisz G.
    Orv Hetil; 2003 Jun 22; 144(25):1251-6. PubMed ID: 12901182
    [Abstract] [Full Text] [Related]

  • 38. Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids.
    Mori K, Minami M, Kirishima T, Kunimoto K, Okita M, Nakayama M, Makiyama A, Yamaoka J, Nakajima T, Yasui K, Itoh Y, Okanoue T.
    Intervirology; 2006 Jun 22; 49(5):274-80. PubMed ID: 16714856
    [Abstract] [Full Text] [Related]

  • 39. Contrasting patterns of response to lamivudine monotherapy in chronic hepatitis B patients.
    Wolters LM, van Nunen AB, Niesters HG, de Man RA.
    Scand J Gastroenterol Suppl; 2000 Jun 22; (232):74-8. PubMed ID: 11232497
    [Abstract] [Full Text] [Related]

  • 40. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine.
    Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Satoh J, Takagi K, Kobayashi M, Ikeda K, Kumada H.
    J Gastroenterol; 2004 Jan 22; 39(1):34-40. PubMed ID: 14767732
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.